GlobeNewswire•October 9, 2019 Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today.…
GlobeNewswire•October 1, 2019 Biopharma star brings extensive translational research experience as company advances its clinical indications OXNARD, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its chief scientific officer. In this role, Dr. Gigi will oversee all CURE’s research and…
GlobeNewswire•August 21, 2019 OXNARD, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) –– CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF)…
Wealth Receives Key Document from Chilean Environmental Agency Regarding Work at the Atacama Project GlobeNewswire•August 15, 2019 VANCOUVER, British Columbia, Aug. 15, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces it has received from the Chilean Environmental Agency an initial work program…
We start our third quarter having acquired enabling new technology that expands our oral drug delivery capabilities, along with a significant capital infusion. We are pleased to share our post-acquisition investor presentation below, integrating the technology acquired from Chemistry Holdings in our product pipeline. Our primary focus will be on the pharmaceutical and nutraceutical cannabinoid…
GlobeNewswire•August 7, 2019 OXNARD, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings…
GlobeNewswire•July 24, 2019 OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using…
GlobeNewswire•July 16, 2019 OXNARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With…
PR Newswire•July 15, 2019 LAKEWOOD, CO, July 15, 2019 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), the largest uranium producer in the U.S., is pleased to announce that our petition, filed jointly with Ur-Energy Inc. under Section 232 of the Trade Expansion Act of 1962, has been…
PR NewswireJuly 12, 2019 DENVER, July 12, 2019 /PRNewswire/ — Ur-Energy Inc. (NYSE American: URG; TSX: URE) (“Ur-Energy”) and Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”) confirm that they are unaware of any decision by the White House with respect to the U.S. Department of Commerce (“DOC”) investigation into the effects of uranium…